Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Xi Chun Hu"'
Autor:
Qing Yuan Zhang, Tao Sun, Yong Mei Yin, Hui Ping Li, Min Yan, Zhong Sheng Tong, Christina P. Oppermann, Yun Peng Liu, Romulo Costa, Man Li, Ying Cheng, Qu Chang Ouyang, Xi Chen, Ning Liao, Xin Hong Wu, Xiao Jia Wang, Ji Feng Feng, Roberto Hegg, G.B. Kanakasetty, Maria A. Coccia-Portugal, Ru Bing Han, Yi Lu, Hai Dong Chi, Ze Fei Jiang, Xi Chun Hu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Aim: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ca
Externí odkaz:
https://doaj.org/article/97a1aeef27ca442790bae5374547f9e7
Autor:
Xin‐Yu Chen, Bin Li, Ye Wang, Juan Jin, Yu Yang, Lei‐Huan Huang, Meng‐Di Yang, Jian Zhang, Bi‐Yun Wang, Zhi‐Ming Shao, Ting Ni, Sheng‐Lin Huang, Xi‐Chun Hu, Zhong‐Hua Tao
Publikováno v:
Cancer Communications, Vol 43, Iss 9, Pp 1003-1026 (2023)
Abstract Background Immune checkpoint inhibitors (ICIs) shed new light on triple‐negative breast cancer (TNBC), but only a minority of patients demonstrate response. Therefore, adaptive immune resistance (AIR) needs to be further defined to guide t
Externí odkaz:
https://doaj.org/article/c221d8e67a8c4f0f8837a2b805d09448
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract While therapies such as chemotherapy combined with immunotherapy, sacituzumab govitecan, and PARP inhibitors are available for metastatic TNBC, on disease progression after these therapies, the mainstay of therapy is chemotherapy. Apatinib i
Externí odkaz:
https://doaj.org/article/b4071ec867574fde99bec257f88072e0
Autor:
Jin-Hu Fan, Su Zhang, Huan Yang, Zong-Bi Yi, Qu-Chang Ouyang, Min Yan, Xiao-Jia Wang, Xi-Chun Hu, Ze-Fei Jiang, Tao Huang, Zhong-Sheng Tong, Shu-Sen Wang, Yong-Mei Yin, Hui Li, Run-Xiang Yang, Hua-Wei Yang, Yue-E. Teng, Tao Sun, Li Cai, Hong-Yuan Li, Xue-Nong Ouyang, Jian-Jun He, Xin-Lan Liu, Shun-E. Yang, Jia-Yu Wang, Bing-He Xu, You-Lin Qiao
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveThis study aimed to explore possible associations between molecular subtypes and site of distant metastasis in advanced breast cancer (ABC).Methods3577 ABC patients were selected from 21 hospitals of seven geographic regions in China from 20
Externí odkaz:
https://doaj.org/article/d59fc4f00f5042a8a6ce6d73845e9301
Autor:
Louis Wing-Cheong, Chow, Pei-Fen, Fu, Lei, Guo, Xi-Chun, Hu, Jun, Jiang, Erich Ferdiansyah, Lie, Jian, Liu, Xiao-Hong, Lu, Yong-Kui, Lu, Hong-Min, Ma, Qin-Guo, Mo, Yan-Xia, Shi, Kun, Wang, Ming-Hao, Wang, Shu, Wang, Shu-Sen, Wang, Xian-Ming, Wang, Xiao-Jia, Wang, Hui-Jing, Wu, Hong-Jian, Yang, He-Rui, Yao, Yi, Zhang, Li, Zhu, On Behalf Of The Asian Institute Of Clinical Oncology Aico Expert Panel
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 23:379-382
There are varying definitions of women at high risk of breast cancer across different institutions, and there are reports suggesting that the breast cancer risk assessment tools have not been well integrated into clinical practice. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c598dba5aceaf46d75c81ba63c13eba
https://doi.org/10.31557/apjcp.2022.23.2.379
https://doi.org/10.31557/apjcp.2022.23.2.379
Autor:
Shuiping Gao, Ru-Jiao Liu, Yang Chen, Yi-qian Wang, Hong Chen, Hui-juan Zhang, Tian-yi Ma, Jia-bing Wang, Xi-Chun Hu, Jian Zhang
Inhibition of the cyclin-dependent kinase (CDK) 4/6-retinoblastoma (Rb) pathway is an effective therapeutic strategy against cancer. Here, we report a novel CDK4/6 inhibitor, BPI-16350, identified from comprehensive screening of a large panel of kina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebdab9c3be3e9cdd377c965ecb9a4ff0
https://doi.org/10.21203/rs.3.rs-1333630/v1
https://doi.org/10.21203/rs.3.rs-1333630/v1
Publikováno v:
NPJ breast cancer. 8(1)
While therapies such as chemotherapy combined with immunotherapy, sacituzumab govitecan, and PARP inhibitors are available for metastatic TNBC, on disease progression after these therapies, the mainstay of therapy is chemotherapy. Apatinib is a small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f8a71ddb56ed7b01daa58501cf9b055
https://pubmed.ncbi.nlm.nih.gov/36127351
https://pubmed.ncbi.nlm.nih.gov/36127351
Autor:
Zhimin Shao, Zhong Hua Wang, Lei Ji, Junjie Li, Wen Jia Zuo, Xi Chun Hu, Min He, Yi-Zhou Jiang
Publikováno v:
Cancer Medicine, Vol 8, Iss 14, Pp 6212-6220 (2019)
Cancer Medicine
Cancer Medicine
Background Endocrine therapy is the preferred treatment for patients with hormone receptor ‐positive metastatic breast cancer (MBC). While visceral metastasis is a negative prognostic factor, few studies have distinguished between the prognoses of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efb1041c1fb0a7d057a69c9e71a98446
https://doi.org/10.1002/cam4.2453
https://doi.org/10.1002/cam4.2453
Autor:
Xin Hong Wu, Hai Dong Chi, Ying Cheng, Min Yan, Zhong Sheng Tong, Hui Ping Li, Ze Fei Jiang, Yi Lu, Man Li, Xi Chen, Tao Sun, Qu Chang Ouyang, Ning Liao, G.B. Kanakasetty, Yong Mei Yin, Yunpeng Liu, Xi Chun Hu, Roberto Hegg, Xiao Jia Wang, Ru Bing Han, Ji Feng Feng, Maria A. Coccia-Portugal, Romulo Costa, Christina Pimentel Oppermann, Q. Zhang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Aim:To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::618ab9aac2f18954d1d66f37dbd4a030
https://doaj.org/article/97a1aeef27ca442790bae5374547f9e7
https://doaj.org/article/97a1aeef27ca442790bae5374547f9e7
Autor:
Biyun Wang, Tao Sun, Yannan Zhao, Shusen Wang, Jian Zhang, Zhonghua Wang, Yue-E Teng, Li Cai, Min Yan, Xiaojia Wang, Zefei Jiang, Yueyin Pan, Jianfeng Luo, Zhimin Shao, Jiong Wu, Xiaomao Guo, Xi-Chun Hu, The GAP Study Group
Publikováno v:
SSRN Electronic Journal.
Background: Platinum is recommended in combination with gemcitabine in the treatment of metastatic triple-negative breast cancer (mTNBC), such as carboplatin plus gemcitabine and cisplatin plus gemcitabine. However, an optimal partner with cisplatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e6992f28610590fd9812e8425b82a3
https://doi.org/10.2139/ssrn.3705293
https://doi.org/10.2139/ssrn.3705293